Late sodium current inhibition: The most promising antiarrhythmic principle in the near future?

Current Medicinal Chemistry

Volumn 21, Issue 11, 2014, Pages 1271-1278

  Frommeyer, G ^a   Milberg, P ^a   Maier, L S ^b   Eckardt, L ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Atrial fibrillation; Late sodium current; Post repolarization refractoriness; Proarrhythmia; Ranolazine; Ventricular fibrillation

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; DRONEDARONE; ERYTHROMYCIN; FLECAINIDE; INAKALANT; POTASSIUM CHANNEL BLOCKING AGENT; QUINIDINE; RANOLAZINE; SODIUM CHANNEL; SOTALOL; VERNAKALANT;

ANTIARRHYTHMIC ACTIVITY; ARTICLE; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART FAILURE; HEART RHYTHM; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; NONHUMAN; QT PROLONGATION; SODIUM CURRENT; TORSADE DES POINTES;

ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; ATRIAL FIBRILLATION; DRUG COMBINATIONS; ELECTROPHYSIOLOGICAL PHENOMENA; HUMANS; SODIUM;

EID: 84896304477     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113209990220     Document Type: Article

References (82)

1. Le Heuzey, J. Y.; De Ferrari, G. M.; Radzik, D.; Santini, M.; Zhu, J.; Davy, J. M. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: The dionysos study. J. Cardiovasc. Electrophysiol., 2010, 21, 597-605.
2. Kober, L.; Torp-Pedersen, C.; McMurray, J. J.; Gotzsche, O.; Levy, S.; Crijns, H.; Amlie, J.; Carlsen, J. Increased mortality after dronedarone therapy for severe heart failure. N. Engl. J. Med., 2008, 358, 2678-2687. (Pubitemid 351860860)
3. Connolly, S. J.; Camm, A. J.; Halperin, J. L.; Joyner, C.; Alings, M.; Amerena, J.; Atar, D.; Avezum, A.; Blomstrom, P.; Borggrefe, M.; Budaj, A.; Chen, S. A.; Ching, C. K.; Commerford, P.; Dans, A.; Davy, J. M.; Delacretaz, E.; Di Pasquale, G.; Diaz, R.; Dorian, P.; Flaker, G.; Golitsyn, S.; Gonzalez-Hermosillo, A.; Granger, C. B.; Heidbuchel, H.; Kautzner, J.; Kim, J. S.; Lanas, F.; Lewis, B. S.; Merino, J. L.; Morillo, C.; Murin, J.; Narasimhan, C.; Paolasso, E.; Parkhomenko, A.; Peters, N. S.; Sim, K. H.; Stiles, M. K.; Tanomsup, S.; Toivonen, L.; Tomcsanyi, J.; Torp-Pedersen, C.; Tse, H. F.; Vardas, P.; Vinereanu, D.; Xavier, D.; Zhu, J.; Zhu, J. R.; Baret-Cormel, L.; Weinling, E.; Staiger, C.; Yusuf, S.; Chrolavicius, S.; Afzal, R.; Hohnloser, S. H. Dronedarone in high-risk permanent atrial fibrillation. N. Engl. J. Med., 2011, 365, 2268-2276.
4. Felser, A.; Blum, K.; Lindinger, P. W.; Bouitbir, J.; Krahenbuhl, S. Mechanisms of hepatocellular toxicity associated with dronedarone - a comparison to amiodarone. Toxicol Sci., 2013, 131, 480-490.
5. * developed with the special contribution of the european heart rhythm association. Europace, 2012, 14, 1385-1413.
6. Milberg, P.; Frommeyer, G.; Uphaus, T.; Kaiser, D.; Osada, N.; Breithardt, G.; Eckardt, L. Electrophysiologic profile of dronedarone on the ventricular level: Beneficial effect on postrepolarization refractoriness in the presence of rapid phase 3 repolarization. J. Cardiovasc. Pharmacol., 2012, 59, 92-100.
7. Burashnikov, A.; Antzelevitch, C. Role of late sodium channel current block in the management of atrial fibrillation. Cardiovasc. Drugs Ther., 2013, 27(1), 79-89.
8. Undrovinas, A.; Maltsev, V. A. Late sodium current is a new therapeutic target to improve contractility and rhythm in failing heart. Cardiovasc. Hematol. Agents Med. Chem., 2008, 6, 348-359.
9. Antzelevitch, C.; Burashnikov, A.; Sicouri, S.; Belardinelli, L. Electrophysiologic basis for the antiarrhythmic actions of ranolazine. Heart Rhythm., 2011, 8, 1281-1290.
10. Zygmunt, A. C.; Eddlestone, G. T.; Thomas, G. P.; Nesterenko, V. V.; Antzelevitch, C. Larger late sodium conductance in m cells contributes to electrical heterogeneity in canine ventricle. Am. J. Physiol. Heart Circ. Physiol., 2001, 281, H689-H697.
11. Persson, F.; Andersson, B.; Duker, G.; Jacobson, I.; Carlsson, L. Functional effects of the late sodium current inhibition by azd7009 and lidocaine in rabbit isolated atrial and ventricular tissue and purkinje fibre. Eur. J. Pharmacol., 2007, 558, 133-143. (Pubitemid 46350691)
12. Burashnikov, A.; Di Diego, J. M.; Zygmunt, A. C.; Belardinelli, L.; Antzelevitch, C. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: Differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation, 2007, 116, 1449-1457. (Pubitemid 47480635)
13. Sossalla, S.; Kallmeyer, B.; Wagner, S.; Mazur, M.; Maurer, U.; Toischer, K.; Schmitto, J. D.; Seipelt, R.; Schondube, F. A.; Hasenfuss, G.; Belardinelli, L.; Maier, L. S. Altered na (+) currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium. J. Am. Coll. Cardiol., 2010, 55, 2330-2342.
14. Guo, D.; Young, L.; Wu, Y.; Belardinelli, L.; Kowey, P. R.; Yan, G. X. Increased late sodium current in left atrial myocytes of rabbits with left ventricular hypertrophy: Its role in the genesis of atrial arrhythmias. Am. J. Physiol. Heart Circ. Physiol., 2010, 298, H1375-H1381.
15. Burashnikov, A.; Pourrier, M.; Gibson, J. K.; Lynch, J. J.; Antzelevitch, C. Rate-dependent effects of vernakalant in the isolated non-remodeled canine left atria are primarily due to block of the sodium channel: Comparison with ranolazine and dl-sotalol. Circ. Arrhythm. Electrophysiol., 2012, 5, 400-408.
16. Bosch, R. F.; Zeng, X.; Grammer, J. B.; Popovic, K.; Mewis, C.; Kuhlkamp, V. Ionic mechanisms of electrical remodeling in human atrial fibrillation. Cardiovasc. Res., 1999, 44, 121-131. (Pubitemid 29431690)
17. + current in a chronic dog model of atrial fibrillation. Circ. Res., 1997, 81, 1045-1052. (Pubitemid 27514955)
18. Wijffels, M. C.; Kirchhof, C. J.; Dorland, R.; Allessie, M. A. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation, 1995, 92, 1954-1968.
19. Wettwer, E.; Christ, T.; Endig, S.; Rozmaritsa, N.; Matschke, K.; Lynch, J. J.; Pourrier, M.; Gibson, J. K.; Fedida, D.; Knaut, M.; Ravens, U. The new antiarrhythmic drug vernakalant: Ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation. Cardiovasc. Res., 2013, 98, 145-154.
20. Song, Y.; Shryock, J. C.; Wagner, S.; Maier, L. S.; Belardinelli, L. Blocking late sodium current reduces hydrogen peroxide-induced arrhythmogenic activity and contractile dysfunction. J. Pharmacol. Exp. Ther., 2006, 318, 214-222.
21. Sossalla, S.; Wagner, S.; Rasenack, E. C.; Ruff, H.; Weber, S. L.; Schondube, F. A.; Tirilomis, T.; Tenderich, G.; Hasenfuss, G.; Belardinelli, L.; Maier, L. S. Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts-role of late sodium current and intracellular ion accumulation. J. Mol. Cell. Cardiol., 2008, 45, 32-43.
22. + channels. J. Clin. Invest., 2006, 116, 3127-3138. (Pubitemid 44878627)
23. Wagner, S.; Ruff, H. M.; Weber, S. L.; Bellmann, S.; Sowa, T.; Schulte, T.; Anderson, M. E.; Grandi, E.; Bers, D. M.; Backs, J.; Belardinelli, L.; Maier, L. S. Reactive oxygen species-activated ca/calmodulin kinase iidelta is required for late i (na) augmentation leading to cellular na and ca overload. Circ. Res., 2011, 108, 555-565.
24. Zhang, T.; Maier, L. S.; Dalton, N. D.; Miyamoto, S.; Ross, J. Jr.; Bers, D. M.; Brown, J. H. The deltac isoform of camkii is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure. Circ. Res., 2003, 92, 912-919. (Pubitemid 36542533)
25. Toischer, K.; Rokita, A. G.; Unsold, B.; Zhu, W.; Kararigas, G.; Sossalla, S.; Reuter, S. P.; Becker, A.; Teucher, N.; Seidler, T.; Grebe, C.; Preuss, L.; Gupta, N.; Schmidt, K.; Lehnart, S. E.; Kruger, M.; Linke, W. A.; Backs, J.; Regitz-Zagrosek, V.; Schafer, K.; Field, L. J.; Maier, L. S.; Hasenfuss, G. Differential cardiac remodeling in preload versus afterload. Circulation, 2010, 122, 993-1003.
26. Fredj, S.; Sampson, K. J.; Liu, H.; Kass, R. S. Molecular basis of ranolazine block of lqt-3 mutant sodium channels: Evidence for site of action. Br. J. Pharmacol., 2006, 148, 16-24. (Pubitemid 43675596)
27. Ju, Y. K.; Saint, D. A.; Gage, P. W. Hypoxia increases persistent sodium current in rat ventricular myocytes. J. Physiol., 1996, 497(Pt 2), 337-347. (Pubitemid 26418103)
28. Huang, B.; El-Sherif, T.; Gidh-Jain, M.; Qin, D.; El-Sherif, N. Alterations of sodium channel kinetics and gene expression in the postinfarction remodeled myocardium. J. Cardiovasc. Electrophysiol., 2001, 12, 218-225. (Pubitemid 32171514)
29. Maltsev, V. A.; Silverman, N.; Sabbah, H. N.; Undrovinas, A. I. Chronic heart failure slows late sodium current in human and canine ventricular myocytes: Implications for repolarization variability. Eur. J. Heart Fail., 2007, 9, 219-227. (Pubitemid 46330143)
30. Frommeyer, G.; Milberg, P.; Witte, P.; Stypmann, J.; Koopmann, M.; Lucke, M.; Osada, N.; Breithardt, G.; Fehr, M.; Eckardt, L. A new mechanism preventing proarrhythmia in chronic heart failure: Rapid phase-iii repolarization explains the low proarrhythmic potential of amiodarone in contrast to sotalol in a model of pacinginduced heart failure. Eur. J. Heart Fail., 2011, 13, 1060-1069.
31. Echt, D. S.; Liebson, P. R.; Mitchell, L. B.; Peters, R. W.; Obias-Manno, D.; Barker, A. H.; Arensberg, D.; Baker, A.; Friedman, L.; Greene, H. L.; et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial. N. Engl. J. Med., 1991, 324, 781-788.
32. Kirchhof, P.; Degen, H.; Franz, M. R.; Eckardt, L.; Fabritz, L.; Milberg, P.; Laer, S.; Neumann, J.; Breithardt, G.; Haverkamp, W. Amiodarone-induced postrepolarization refractoriness suppresses induction of ventricular fibrillation. J. Pharmacol. Exp. Ther., 2003, 305, 257-263. (Pubitemid 36373859)
33. Frommeyer, G.; Schmidt, M.; Clauss, C.; Kaese, S.; Stypmann, J.; Pott, C.; Eckardt, L.; Milberg, P. Further insights into the underlying electrophysiological mechanisms for reduction of atrial fibrillation by ranolazine in an experimental model of chronic heart failure. Eur. J. Heart Fail., 2012, 14, 1322-1331.
34. Sicouri, S.; Glass, A.; Belardinelli, L.; Antzelevitch, C. Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm., 2008, 5, 1019-1026.
35. Murdock, D. K.; Overton, N.; Kersten, M.; Kaliebe, J.; Devecchi, F. The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation. Indian Pacing Electrophysiol. J., 2008, 8, 175-181.
36. Antzelevitch, C.; Belardinellim L.; Zygmunt, A. C.; Burashnikov, A.; Di Diego, J. M.; Fish, J. M.; Cordeiro, J. M.; Thomas, G. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation, 2004, 110, 904-910. (Pubitemid 39136212)
37. Kloner, R. A.; Dow, J. S.; Bhandari, A. The antianginal agent ranolazine is a potent antiarrhythmic agent that reduces ventricular arrhythmias: Through a mechanism favoring inhibition of late sodium channel. Cardiovasc. Ther., 2011, 29, e36-e41.
38. Miles, R. H.; Passman, R.; Murdock, D. K. Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting. Am. J. Cardiol., 2011, 108, 673-676.
39. Murdock, D. K.; Kersten, M.; Kaliebe, J.; Larrain, G. The use of oral ranolazine to convert new or paroxysmal atrial fibrillation: A review of experience with implications for possible "pill in the pocket" approach to atrial fibrillation. Indian Pacing Electrophysiol. J., 2009, 9, 260-267.
40. Maier, L. S. Ranolazine for atrial fibrillation: Buy one get three beneficial mechanisms! Eur. J. Heart Fail., 2012, 14, 1313-1315.
41. Kumar, K.; Nearing, B. D.; Carvas, M.; Nascimento, B. C.; Acar, M.; Belardinelli, L.; Verrier, R. L. Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart. J. Cardiovasc. Electrophysiol., 2009, 20, 796-802.
42. Scirica, B. M.; Morrow, D. A.; Hod, H.; Murphy, S. A.; Belardinelli, L.; Hedgepeth, C. M.; Molhoek, P.; Verheugt, F. W.; Gersh, B. J.; McCabe, C. H.; Braunwald, E. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non st-segment elevation acute coronary syndrome: Results from the metabolic efficiency with ranolazine for less ischemia in non st-elevation acute coronary syndrome thrombolysis in myocardial infarction 36 (merlin-timi 36) randomized controlled trial. Circulation, 2007, 116, 1647-1652. (Pubitemid 47537839)
43. Milberg, P.; Frommeyer, G.; Ghezelbash, S.; Rajamani, S.; Osada, N.; Razvan, R.; Belardinelli, L.; Breithardt, G.; Eckardt, L. Sodium channel block by ranolazine in an experimental model of stretchrelated atrial fibrillation: Prolongation of interatrial conduction time and increase in post-repolarization refractoriness. Europace, 2013, 15(5), 761-9.
44. Watanabe, H.; Watanabe, I.; Nakai, T.; Oshikawa, N.; Kunimoto, S.; Masaki, R.; Kojima, T.; Saito, S.; Ozawa, Y.; Kanmatuse, K. Frequency-dependent electrophysiological effects of flecainide, nifekalant and d, l-sotalol on the human atrium. Jpn. Circ. J., 2001, 65, 1-6.
45. Dhalla, A. K.; Wang, W. Q.; Dow, J.; Shryock, J. C.; Belardinelli, L.; Bhandari, A.; Kloner, R. A. Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion. Am. J. Physiol. Heart Circ. Physiol., 2009, 297, H1923-H1929.
46. Sossalla, S.; Maier, L. S. Role of ranolazine in angina, heart failure, arrhythmias, and diabetes. Pharmacol. Ther., 2012, 133, 311-323.
47. Moss, A. J.; Zareba, W.; Schwarz, K. Q.; Rosero, S.; McNitt, S.; Robinson, J. L. Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-qt syndrome. J. Cardiovasc. Electrophysiol., 2008, 19, 1289-1293.
48. Morita, N.; Lee, J. H.; Xie, Y.; Sovari, A.; Qu, Z.; Weiss, J. N.; Karagueuzian, H. S. Suppression of re-entrant and multifocal ventricular fibrillation by the late sodium current blocker ranolazine. J. Am. Coll. Cardiol., 2011, 57, 366-375.
49. Frommeyer, G.; Rajamani, S.; Grundmann, F.; Stypmann, J.; Osada, N.; Breithardt, G.; Belardinelli, L.; Eckardt, L.; Milberg, P. New insights into the beneficial electrophysiologic profile of ranolazine in heart failure: Prevention of ventricular fibrillation with increased postrepolarization refractoriness and without drug-induced proarrhythmia. J. Card. Fail., 2012, 18, 939-949.
50. Milberg, P.; Tegelkamp, R.; Osada, N.; Schimpf, R.; Wolpert, C.; Breithardt, G.; Borggrefe, M.; Eckardt, L. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short qt syndrome. J. Cardiovasc. Electrophysiol., 2007, 18, 658-664. (Pubitemid 46800513)
51. + current. J. Cardiovasc. Pharmacol., 2008, 51, 581-589.
52. Kirchhof, P. F.; Fabritz, C. L.; Franz, M. R. Postrepolarization refractoriness versus conduction slowing caused by class i antiarrhythmic drugs: Antiarrhythmic and proarrhythmic effects. Circulation, 1998, 97, 2567-2574. (Pubitemid 28294504)
53. Kloner, R. A.; Dow, J. S.; Bhandari, A. First direct comparison of the late sodium current blocker ranolazine to established antiarrhythmic agents in an ischemia/reperfusion model. J. Cardiovasc. Pharmacol. Ther., 2011, 16, 192-196.
54. Nieminen, T.; Nanbu, D. Y.; Datti, I. P.; Vaz, G. R.; Tavares, C. A.; Pegler, J. R.; Nearing, B. D.; Belardinelli, L.; Verrier, R. L. Antifibrillatory effect of ranolazine during severe coronary stenosis in the intact porcine model. Heart Rhythm., 2011, 8, 608-614.
55. Song, Y.; Shryock, J. C.; Wu, L.; Belardinelli, L. Antagonism by ranolazine of the pro-arrhythmic effects of increasing late ina in guinea pig ventricular myocytes. J. Cardiovasc. Pharmacol., 2004, 44, 192-199. (Pubitemid 38982162)
56. 2+ exchanger suppresses torsades de pointes in an intact heart model of long qt syndrome-2 and long qt syndrome-3. Heart Rhythm., 2008, 5, 1444-1452.
57. Milberg, P.; Frommeyer, G.; Kleideiter, A.; Fischer, A.; Osada, N.; Breithardt, G.; Fehr, M.; Eckardt, L. Antiarrhythmic effects of free polyunsaturated fatty acids in an experimental model of lqt2 and lqt3 due to suppression of early afterdepolarizations and reduction of spatial and temporal dispersion of repolarization. Heart Rhythm., 2011, 8, 1492-1500.
58. Antoons, G.; Oros, A.; Beekman, J. D.; Engelen, M. A.; Houtman, M. J.; Belardinelli, L.; Stengl, M.; Vos, M. A. Late na (+) current inhibition by ranolazine reduces torsades de pointes in the chronic atrioventricular block dog model. J. Am. Coll. Cardiol., 2010, 55, 801-809.
59. Kumar, K.; Nearing, B. D.; Bartoli, C. R.; Kwaku, K. F.; Belardinelli, L.; Verrier, R. L. Effect of ranolazine on ventricular vulnerability and defibrillation threshold in the intact porcine heart. J. Cardiovasc. Electrophysiol., 2008, 19, 1073-1079.
60. Murdock, D. K.; Kaliebe, J.; Overton, N. Ranolozine-induced suppression of ventricular tachycardia in a patient with nonischemic cardiomyopathy: A case report. Pacing Clin. Electrophysiol., 2008, 31, 765-768. (Pubitemid 351749321)
61. Bunch, T. J.; Mahapatra, S.; Murdock, D.; Molden, J.; Weiss, J. P.; May, H. T.; Bair, T. L.; Mader, K. M.; Crandall, B. G.; Day, J. D.; Osborn, J. S.; Muhlestein, J. B.; Lappe, D. L.; Anderson, J. L. Ranolazine reduces ventricular tachycardia burden and icd shocks in patients with drug-refractory icd shocks. Pacing Clin. Electrophysiol., 2011, 34, 1600-1606.
62. Scirica, B. M.; Braunwald, E.; Belardinelli, L.; Hedgepeth, C. M.; Spinar, J.; Wang, W.; Qin, J.; Karwatowska-Prokopczuk, E.; Verheugt, F. W.; Morrow, D. A. Relationship between nonsustained ventricular tachycardia after non-st-elevation acute coronary syndrome and sudden cardiac death: Observations from the metabolic efficiency with ranolazine for less ischemia in non-st-elevation acute coronary syndrome-thrombolysis in myocardial infarction 36 (merlin-timi 36) randomized controlled trial. Circulation, 2010, 122, 455-462.
63. Sicouri, S.; Burashnikov, A.; Belardinelli, L.; Antzelevitch, C. Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria. Circ. Arrhythm. Electrophysiol., 2010, 3, 88-95.
64. Burashnikov, A.; Sicouri, S.; Di Diego, J. M.; Belardinelli, L.; Antzelevitch, C. Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation. J. Am. Coll. Cardiol., 2010, 56, 1216-1224.
65. Frommeyer, G.; Kaiser, D.; Uphaus, T.; Kaese, S.; Osada, N.; Rajamani, S.; Belardinelli, L.; Breithardt, G.; Eckardt, L.; Milberg, P. Effect of ranolazine on ventricular repolarization in class iii antiarrhythmic drug-treated rabbits. Heart Rhythm., 2012, 9, 2051-2058.
66. Milberg, P.; Eckardt, L.; Bruns, H. J.; Biertz, J.; Ramtin, S.; Reinsch, N.; Fleischer, D.; Kirchhof, P.; Fabritz, L.; Breithardt, G.; Haverkamp, W. Divergent proarrhythmic potential of macrolide antibiotics despite similar qt prolongation: Fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. J. Pharmacol. Exp. Ther., 2002, 303, 218-225.
67. Milberg, P.; Hilker, E.; Ramtin, S.; Cakir, Y.; Stypmann, J.; Engelen, M. A.; Monnig, G.; Osada, N.; Breithardt, G.; Haverkamp, W.; Eckardt, L. Proarrhythmia as a class effect of quinolones: Increased dispersion of repolarization and triangulation of action potential predict torsades de pointes. J. Cardiovasc. Electrophysiol., 2007, 18, 647-654. (Pubitemid 46800509)
68. Milberg, P.; Ramtin, S.; Monnig, G.; Osada, N.; Wasmer, K.; Breithardt, G.; Haverkamp, W.; Eckardt, L. Comparison of the in vitro electrophysiologic and proarrhythmic effects of amiodarone and sotalol in a rabbit model of acute atrioventricular block. J. Cardiovasc. Pharmacol., 2004, 44, 278-286. (Pubitemid 39129444)
69. Milberg, P.; Pott, C.; Frommeyer, G.; Fink, M.; Ruhe, M.; Matsuda, T.; Baba, A.; Klocke, R.; Quang, T. H.; Nikol, S.; Stypmann, J.; Osada, N.; Muller, F. U.; Breithardt, G.; Noble, D.; Eckardt, L. Acute inhibition of the na (+)/ca (2+) exchanger reduces proarrhythmia in an experimental model of chronic heart failure. Heart Rhythm., 2012, 9, 570-578.
70. Verrier, R. L.; Pagotto, V. P.; Kanas, A. F.; Sobrado, M. F.; Nearing, B. D.; Zeng, D.; Belardinelli, L. Low doses of ranolazine and dronedarone in combination exert potent protection against atrial fibrillation and vulnerability to ventricular arrhythmias during acute myocardial ischemia. Heart Rhythm., 2013, 10, 121-127.
71. Nattel, S.; Burstein, B.; Dobrev, D. Atrial remodeling and atrial fibrillation: Mechanisms and implications. Circ. Arrhythm. Electrophysiol., 2008, 1, 62-73.
72. McMurray, J. J.; Adamopoulos, S.; Anker, S. D.; Auricchio, A.; Bohm, M.; Dickstein, K.; Falk, V.; Filippatos, G.; Fonseca, C.; Gomez-Sanchez, M. A.; Jaarsma, T.; Kober, L.; Lip, G. Y.; Maggioni, A. P.; Parkhomenko, A.; Pieske, B. M.; Popescu, B. A.; Ronnevik, P. K.; Rutten, F. H.; Schwitter, J.; Seferovic, P.; Stepinska, J.; Trindade, P. T.; Voors, A. A.; Zannad, F.; Zeiher, A.; Bax, J. J.; Baumgartner, H.; Ceconi, C.; Dean, V.; Deaton, C.; Fagard, R.; Funck-Brentano, C.; Hasdai, D.; Hoes, A.; Kirchhof, P.; Knuuti, J.; Kolh, P.; McDonagh, T.; Moulin, C.; Reiner, Z.; Sechtem, U.; Sirnes, P. A.; Tendera, M.; Torbicki, A.; Vahanian, A.; Windecker, S.; Bonet, L. A.; Avraamides, P.; Ben Lamin, H. A.; Brignole, M.; Coca, A.; Cowburn, P.; Dargie, H.; Elliott, P.; Flachskampf, F. A.; Guida, G. F.; Hardman, S.; Iung, B.; Merkely, B.; Mueller, C.; Nanas, J. N.; Nielsen, O. W.; Orn, S.; Parissis, J. T.; Ponikowski, P. Esc guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the european society of cardiology. Developed in collaboration with the heart failure association (hfa) of the esc. Eur. J. Heart Fail., 2012, 14, 803-869.
73. Goldstein, R. N.; Khrestian, C.; Carlsson, L.; Waldo, A. L. Azd7009: A new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model. J. Cardiovasc. Electrophysiol., 2004, 15, 1444-1450. (Pubitemid 40013678)
74. Carlsson, L.; Chartier, D.; Nattel, S. Characterization of the in vivo and in vitro electrophysiological effects of the novel antiarrhythmic agent azd7009 in atrial and ventricular tissue of the dog. J. Cardiovasc. Pharmacol., 2006, 47, 123-132. (Pubitemid 44378235)
75. Crijns, H. J.; Van Gelder, I. C.; Walfridsson, H.; Kulakowski, P.; Ronaszeki, A.; Dedek, V.; Malm, A.; Almgren, O. Safe and effective conversion of persistent atrial fibrillation to sinus rhythm by intravenous azd7009. Heart Rhythm., 2006, 3, 1321-1331. (Pubitemid 44636926)
76. Geller, J. C.; Egstrup, K.; Kulakowski, P.; Rosenqvist, M.; Jansson, M. A.; Berggren, A.; Edvardsson, N.; Sager, P.; Crijns, H. J. Rapid conversion of persistent atrial fibrillation to sinus rhythm by intravenous azd7009. J. Clin. Pharmacol., 2009, 49, 312-322.
77. Belardinelli, L.; Liu, G.; Smith-Maxwell, C.; Wang, W. Q.; El-Bizri, N.; Hirakawa, R.; Karpinski, S.; Hong, L. C.; Hu, L.; Li, X. J.; Crumb, W.; Wu, L.; Koltun, D.; Zablocki, J.; Yao, L.; Dhalla, A. K.; Rajamani, S.; Shryock, J. C. A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias. J. Pharmacol. Exp. Ther., 2013, 344, 23-32.
78. Kowey, P. R.; Dorian, P.; Mitchell, L. B.; Pratt, C. M.; Roy, D.; Schwartz, P. J.; Sadowski, J.; Sobczyk, D.; Bochenek, A.; Toft, E. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: A randomized, double-blind, placebocontrolled trial. Circ. Arrhythm. Electrophysiol., 2009, 2, 652-659.
79. Stiell, I. G.; Roos, J. S.; Kavanagh, K. M.; Dickinson, G. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm. Am. Heart J., 2010, 159, 1095-1101.
80. Camm, A. J.; Capucci, A.; Hohnloser, S. H.; Torp-Pedersen, C.; Van Gelder, I. C.; Mangal, B.; Beatch, G. A randomized activecontrolled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J. Am. Coll. Cardiol., 2011, 57, 313-321.
81. Torp-Pedersen, C.; Camm, A. J.; Butterfield, N. N.; Dickinson, G.; Beatch, G. N. Vernakalant: Conversion of atrial fibrillation in patients with ischemic heart disease. Int. J. Cardiol., 2013, 166(1), 147-151.
82. Morrow, D. A.; Scirica, B. M.; Karwatowska-Prokopczuk, E.; Murphy, S. A.; Budaj, A.; Varshavsky, S.; Wolff, A. A.; Skene, A.; McCabe, C. H.; Braunwald, E. Effects of ranolazine on recurrent cardiovascular events in patients with non-st-elevation acute coronary syndromes: The merlin-timi 36 randomized trial. JAMA., 2007, 297, 1775-1783. (Pubitemid 46658646)